NCT06940427

Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: University of Wisconsin, Madison · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to gain more information about how fibroblast activation protein inhibitor (FAPI) binds to a certain type of cells in fibrotic lung tissue and how this information can be used to better diagnose and track fibrotic lung disease activity. Participants will undergo up to 4 PET/MRI scans using the FAPI radiotracer.

Detailed description

Researchers aim to develop a non-invasive PET/MRI imaging tool using FAPI as a PET radiotracer and MRI to assess the presence and extent of fibrogenesis (the process that leads to fibrosis and scarring) in the lungs.

Conditions

• Fibrosis Lung

Interventions

Type	Name	Description
DRUG	FAPI tracer	radioactive substance called a "tracer" injected into the arm
DEVICE	PET/MRI	positron emission tomography (PET) takes pictures of inside of the body

Timeline

• Start date: 2025-11-19
• Primary completion: 2027-09-01
• Completion: 2027-09-01
• First posted: 2025-04-23
• Last updated: 2026-03-11

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study
• FDA-regulated device study